Merck-Teva Legal Wrangle Over Januvia "R&D" In India
Merck & Co continues to keep a hawk eye on alleged infringement activities in India pertaining to its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride). It has hauled Teva to court for allegedly manufacturing and selling sitagliptin, though the Israeli multinational has claimed that its efforts were geared only towards regulatory submissions.
You may also be interested in...
Indian companies have cried foul over what they claim are "unethical" practices deployed by foreign firms in the legal arena, among others, to safeguard their "patent monopoly".
Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), or hope to introduce copies of these on the domestic market, infringing on its patents.
The Delhi High Court has permanently enjoined Glenmark Pharmaceuticals Ltd from making and selling its generic version of Merck & Co's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride). The Indian firm has been found to have infringed the sitagliptin patent.